Parkinson's disease dementia and dementia with Lewy bodies Mental and Behavioural Disorders Dementia
Conditions
Interventions
Goal setting:
1. All participants will collaboratively agree problem areas which are formulated in up to three personal rehabilitation goals using the Bangor Goal Setting Interview (BG
Sponsors
Betsi Cadwaladr University Health Board
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Current inclusion criteria as of 22/06/2015: 1. Diagnosis of Parkinson's disease (PD) according to the UK PD Brain Bank Diagnostic Criteria and a diagnosis of PD dementia according to the Movement Disorder Society consensus criteria or 2. Diagnosis of Dementia with Lewy Bodies (DLB) according to the DLB Consortium consensus criteria. 3. Clinical diagnosis of mild to moderate dementia with an ACE-III score of =82 4. Participants will preferably have a carer or family member who is willing to participate but this is not an absolute requirement 5. Participants should be on stable medication for their Parkinsonism and cognition (including acetylcholinesterase inhibitors) for four weeks prior to commencement with no changes planned for the duration of the intervention. Any unplanned changes in medication during the intervention will be documented Previous inclusion criteria: 1. Diagnosis of Parkinson's disease (PD) according to the UK PD Brain Bank Diagnostic Criteria and a diagnosis of PD dementia according to the Movement Disorder Society consensus criteria or; 2. Diagnosis of Dementia with Lewy Bodies (DLB) according to the DLB Consortium consensus criteria. 3. Clinical diagnosis of mild to moderate dementia with an ACE-III score of <80 4. Participants will preferably have a carer or family member who is willing to participate but this is not an absolute requirement 5. Participants should be on stable medication for their Parkinsonism and cognition (including acetylcholinesterase inhibitors) for four weeks prior to commencement with no changes planned for the duration of the intervention. Any unplanned changes in medication during the intervention will be documented
Exclusion criteria
Exclusion criteria: 1. Lack of stability of Parkinson's disease (PD) medications, cognitive enhancers or psychotropic medication or substantial additions to medication in the four weeks before the trial or planned changes during the period of the trial 2. Other major psychiatric disorder not related to PD 3. Major depression 4. Other significant neurological disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Participants’ performance and satisfaction on goals, identified through the Bangor Goal-Setting Interview measure are rated at baseline and at follow-up visits (a 2 month post-intervention visit and a 6 month follow-up visit) | — |
Secondary
| Measure | Time frame |
|---|---|
| For PD dementia patients these cover the domains of cognition, mood, behaviour, everyday functional activity, motor severity, quality of life, self-efficacy, and carer ratings (where available) of patients’ performance on goals identified during the BGSI interview. Carers’ outcomes will include quality of life, stress and health. Cognition: 1. Global cognition will be measured using the Addenbrooke's Cognitive Examination-III (ACE-III) (at screening and at the 6-month follow-up visit). 2. Assessments of executive function will be the Trail Making Test (TMT), and the letter fluency tests from the Delis-Kaplan Executive Function System (both measured at each time point). 3. Attention will be assessed using the Test of Everyday Attention (at each time point). 4. Memory will be assessed using the Rivermead Behavioural Memory Test, story recall sub-test (at each time point). Mood and behaviour: 1. Mood will be assessed at each time point using the Hospital Anxiety and Depression Scale which contains two subscales: anxiety and depression. 2. Behavioural assessment will include delusions and hallucinations measured using the Neuropsychiatric Inventory Questionnaire (this will be measured at the baseline and 6-month follow-up visits). 3. The Unified Parkinson’s Disease Rating Scale will be used to assess the motor symptoms of Parkinsonism in PD and DLB and also assess function and activities of daily living (both will be used at the baseline and 6-month follow-up visits). 4. Quality of life will be assessed in PD and DLB using the abbreviated Parkinson’s disease quality of life scale (PDQ-8) and the WHO Quality of Life – BREF (WHOQOL-BREF) (both will be used at the each time point). 5. The WHOQOL-BREF will also be used for carers (at each time point). 6. In order to assess a general | — |
Countries
United Kingdom
Contacts
Public ContactTam Watermeyer
Outcome results
None listed